News

Symphogen Names Martin Olin Chief Financial Officer and Receives 2nd Tranche from €100 Million 2011 Financing

Symphogen Presents Positive Rozrolimupab (SYM001) Phase 2 Trial Results in ITP at ASH

Symphogen Announces Initiation of Phase 2 Trial of Sym004 EGFR Antibody Mixture in Patients with Squamous Cell Carcinoma of Head and Neck Cancer

Calendar

	2012 National Biotechnology Conference
	Speaker: Torben P. Frandsen, Vice President of PreClinical R&D Support

• May 21 - 23, 2012 San Diego, CA

	Informa's Comparability for Biologics 2012
	Speaker: Andrea Porchia, CMC Manager

• May 22 - 23, 2012 Prague, Czech Rep.

	IBC’s 8th Annual Cell Line Development & Engineering
	Speaker: Søren K. Rasmussen, Principal Scientist

• June 6 - 8, 2012 San Francisco, CA, USA

	13th Drug Discovery & Drug Development Leaders Summit 2012
	Speaker: Johan Lantto, Principal Scientist

• June 11 - 12, 2012 Zurich, Switzerland

Shortcuts